|
Mar 13
|
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders
|
|
Feb 27
|
Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value
|
|
Feb 19
|
Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)
|
|
Feb 18
|
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
|
|
Feb 18
|
Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now
|
|
Feb 13
|
Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
|
|
Jan 29
|
Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO
|
|
Oct 9
|
Jaguar Health Inc (JAGX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Financial ...
|
|
Oct 8
|
Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial
|
|
Oct 2
|
Jaguar’s diarrhoea drug shows benefit in Phase III breast cancer subgroup
|
|
Oct 1
|
Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer
|
|
Aug 15
|
Jaguar Health Second Quarter 2024 Earnings: Misses Expectations
|
|
Aug 13
|
Jaguar Health Reports Second Quarter 2024 Financial Results
|
|
Aug 12
|
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients
|
|
Jul 31
|
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
|
|
Jul 23
|
Jaguar Health shares slump following Phase III Mytesi failure
|
|
Jul 23
|
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
|
|
Jun 26
|
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
|
|
Jun 21
|
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
|
|
Jun 12
|
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
|